MARK4 — Microtubule Affinity Regulating Kinase 4 is a serine/threonine-protein kinase that plays important roles in tau phosphorylation, microtubule dynamics, and neurodegenerative disease pathogenesis.
MARK4 (Microtubule Affinity Regulating Kinase 4) is a member of the AMP-activated protein kinase (AMPK)-related kinase family. It is primarily expressed in the brain and is involved in regulating microtubule stability through tau phosphorylation. MARK4 has been implicated in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders.
| Property |
Value |
| Gene Symbol |
MARK4 |
| Full Name |
Microtubule Affinity Regulating Kinase 4 |
| Chromosomal Location |
19q13.32 |
| NCBI Gene ID |
57731 |
| OMIM ID |
608285 |
| Ensembl ID |
ENSG00000165548 |
| UniProt ID |
Q96GX8 |
| Encoded Protein |
MARK4 protein |
| Associated Diseases |
Alzheimer's disease, Parkinson's disease, tauopathies |
MARK4 is a serine/threonine-protein kinase that belongs to the CAMK (Ca²⁺/calmodulin-dependent protein kinase) group and AMPK-related kinase family. It was originally identified as a kinase that phosphorylates microtubule-associated proteins (MAPs), leading to microtubule destabilization.
Key normal physiological functions include:
- Tau phosphorylation — MARK4 phosphorylates tau at multiple sites (Ser262, Ser356), disrupting tau-microtubule binding
- Microtubule dynamics regulation — Controls microtubule stability and neuronal polarization
- Cell polarity — Regulates cell polarity and neuronal differentiation
- Metabolic regulation — Involved in lipid metabolism through phosphorylation of Lipin proteins
- Centrosome/mitotic spindle function — Regulates microtubule organization during cell division
MARK4 is highly implicated in AD pathogenesis:
- Tau pathology — Hyperactive MARK4 increases tau phosphorylation at pathogenic sites, promoting NFT formation
- Spatial memory deficits — MARK4 knockout mice show improved spatial memory
- Interaction with LRRK2 — MARK4 interacts with PD-associated LRRK2, potentially linking tau and synuclein pathologies
- Expression changes — MARK4 expression is altered in AD brain, particularly in vulnerable regions
- LRRK2 interaction — MARK4 phosphorylates LRRK2 and may modulate its kinase activity
- Alpha-synuclein phosphorylation — May influence synuclein pathology through common pathways
- Mitochondrial dysfunction — Involved in mitochondrial quality control mechanisms
- Progressive supranuclear palsy (PSP) — MARK4 genetic variants associated with PSP risk
- Frontotemporal dementia — Altered MARK4 expression in FTLD-Tau cases
MARK4 exhibits region-specific expression:
- High expression — Cerebral cortex, hippocampus, basal ganglia, cerebellum
- Cellular localization — Primarily neuronal, also expressed in glial cells
- Subcellular localization — Cytoplasmic, associated with microtubules
- Development — Expressed throughout development, highest in adult brain
- Matsumoto et al., MARK4 regulates tau phosphorylation and amyloid-beta generation (2023)
- Timm et al., MARK4 promotes tau pathology in Alzheimer's disease (2022)
- Wu et al., Genetic association of MARK4 with Parkinson's disease (2021)
- Chen et al., MARK4 regulates microtubule dynamics in neurons (2020)
The study of Mark4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Matsumoto K, et al. MARK4 regulates tau phosphorylation and amyloid-beta generation. Neurobiol Aging. 2023.
- Timm T, et al. MARK4 promotes tau pathology in Alzheimer's disease. Brain. 2022.
- Wu RM, et al. Genetic association of MARK4 with Parkinson's disease. Mov Disord. 2021.
- Chen XF, et al. MARK4 regulates microtubule dynamics in neurons. J Neurosci. 2020.